Skip to main content
Caplight Logo









EtiraRx

EtiraRx

Private
Dallas, TexasHealthcare & Life Scienceshttps://etira.life/

Last Round

Accelerator

Apr 14, 2026

Total Funding Raised

$3.42M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

EtiraRx is a biopharmaceutical company that develops novel cancer therapeutics to treat cancers by validating molecular drivers and evaluating mechanisms of therapy resistance.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

oncology therapeuticssmall molecule drugstherapy resistant cancerdrug resistant cancerclinical stage biopharmaendoplasmic reticulum stressER stressmetastatic cancertumor heterogeneitypre-revenue biotechoral cancer therapyphase 1 clinical trialcancer drug developmenttriple negative breast cancerTNBCpancreatic cancer therapyovarian cancer therapy

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

EtiraRx Comparables

Compare EtiraRx with similar companies based on industry and business-model similarity.

EtiraRx comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Bold Therapeutics Inc.
77%
MicroQuin
74%
Hibercell
72%

EtiraRx Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
AcceleratorApr 14, 2026
SeedOct 4, 2023
GrantAug 15, 2021

EtiraRx Investors

Notable investors and investment history

EtiraRx investors
InvestorRounds
National Cancer InstituteGrant
MassChallenge IsraelAccelerator

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 14, 2026

    Received funding from MassChallenge.

  • Nov 10, 2025

    Monthly visitors increased 62% MoM.

EtiraRx Filings

Explore SEC and related filing metadata, where available.

EtiraRx filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about EtiraRx's valuation, stock price, and market status.

Is EtiraRx a public or private company?

EtiraRx is a private company.

What is the current stock price of EtiraRx?

EtiraRx is a private company with no public stock price. No recent secondary market data is available.

How much is EtiraRx worth (valuation)?

Valuation information for EtiraRx is not publicly available.

Can I buy EtiraRx stock?

EtiraRx shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was EtiraRx's last funding round?

EtiraRx's most recent funding round was Accelerator on April 14, 2026.

Who are the main investors in EtiraRx?

Key investors in EtiraRx include National Cancer Institute, MassChallenge.

Will EtiraRx IPO soon?

No public IPO plans have been announced for EtiraRx.

How can I track EtiraRx secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor EtiraRx's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersDallas, Texas
Employee Range3
Year Founded2018
Last FundingApr 14, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?